Mitchell Coppedge
Family Medicine · Chickasha, OKNPI 1902887482
Payments from drug & device makers
Across 111 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$453
- GSK$197
- Sumitomo Pharma America, Inc.$119
- Bayer$114
- Johnson & Johnson$97
- Abbott$93
- plus $756 from 22 others
What the payments were for
- Food & beverage$1,828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $453 |
| GSK | 12 | $197 |
| Sumitomo Pharma America, Inc. | 6 | $119 |
| Bayer | 7 | $114 |
| Johnson & Johnson | 7 | $97 |
| Abbott | 6 | $93 |
| Sunovion Pharmaceuticals Inc. | 10 | $83 |
| Boehringer Ingelheim | 4 | $80 |
| AbbVie | 3 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| AstraZeneca | 4 | $59 |
| Mannkind Corporation | 3 | $53 |
| Amgen | 3 | $45 |
| Tersera Therapeutics LLC | 2 | $38 |
| Astellas Pharma US Inc | 2 | $34 |
| Dexcom, Inc. | 2 | $31 |
| Pfizer | 2 | $26 |
| Merck | 2 | $26 |
| Lilly USA, LLC | 2 | $24 |
| Medtronic | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Exact Sciences | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Pernix Therapeutics Holdings, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$114
How this compares
$1,828 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 309 | $189,791 |
| OzempicSemaglutide | 141 | $161,625 |
| TrulicityDulaglutide | 84 | $94,006 |
| JardianceEmpagliflozin | 73 | $93,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $61,205 |
| FarxigaDapagliflozin Propanediol | 48 | $40,538 |
| EntrestoSacubitril/Valsartan | 55 | $38,379 |
| MounjaroTirzepatide | 29 | $35,482 |
| JanuviaSitagliptin Phosphate | 28 | $33,464 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $29,524 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $25,327 |
| XareltoRivaroxaban | 44 | $21,425 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $18,162 |
| InvokanaCanagliflozin | 16 | $16,035 |
| QuliptaAtogepant | 12 | $12,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $26 | $199,717336 claims |
| Novo NordiskOzempic, Rybelsus | $453 | $173,062153 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $24 | $129,488113 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $80 | $100,40886 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $197 | $79,367102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $59 | $65,86682 claims |
| NovartisEntresto | $12 | $38,37955 claims |
| Johnson & JohnsonXarelto, Invokana | $97 | $37,46160 claims |
| MerckJanuvia | $26 | $33,46428 claims |
| AbbVieQulipta, Vraylar | $65 | $20,12723 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $10,47318 claims |
| BayerKerendia | $114 | $8,23213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Chickasha
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.